VIATRIS (MYLAN, INC)

Lobbying client. Federal LDA filings.

Connected on the graph

Inbound (6)

date	from	type	amount	source
—	Christopher Buki	lobbied_for	—	lda_lobbyist_client
—	Shimon Stein	lobbied_for	—	lda_lobbyist_client
—	Kristi Remington	lobbied_for	—	lda_lobbyist_client
—	Ashley Davis	lobbied_for	—	lda_lobbyist_client
—	Malloy Mcdaniel	lobbied_for	—	lda_lobbyist_client
2026-01-01	S-3 GROUP	lobbies_for	$60,000	lda_filing

Outbound (5)

date	type	to	amount	role	source
2026-01-01	lobbies_on_bill	HR 1843 — To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug	—	H.R. 1843	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1041 — Affordable Prescriptions for Patients Act	—	S.1041	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1096 — Preserve Access to Affordable Generics and Biosimilars Act	—	S.1096	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 1302 — Increasing Transparency in Generic Drug Applications Act	—	S.1302	lobbying_bill_mention
2026-01-01	lobbies_on_bill	S 527 — Prescription Pricing for the People Act of 2025	—	S.527	lobbying_bill_mention

Source id: 66077
General description: Generics and specialty pharmaceutical company
State: PA
Country: US
Principal place of business: US
Effective date: 2025-02-01
Total spend (across 1 ingested filings): $60,000

Filings

Posted	Type	Year	Lobbying firm	Income
2026-04-17	`Q1`	2026	S-3 GROUP	$60,000

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.